Observational studyJournal of behavioral medicine2025
The impact of experiential avoidance on anxiety and depressive disorders in hematological cancer patients.
Observational study in Journal of behavioral medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Anxiety disorders and/or depressive disorders co-occurring with hematological cancer are an additional burden for patients. Experiential avoidance (EA; efforts to avoid negative emotions, thoughts, or memories) is an empirically evident transdiagnostic factor for the onset and maintenance of anxiety and depressive disorders in non-cancer populations. There is lack of evidence on the impact of EA in predicting anxiety and depression in cancer patients. A total of 291 patients with hematological cancer (60% male, mean age 55 years) were included in this cross-sectional observational study. Participants were assessed using the Structured Clinical Interview for DSM-5 mental disorders (SCID-5). EA was assessed via self-report using the Brief Experiential Avoidance Questionnaire (BEAQ). Hierarchical binomial logistic regression was conducted in order to estimate the impact of EA on anxiety and depressive disorders. A total of 38 patients (13.3%) met the diagnostic criteria for a current anxiety disorder, while 49 patients (17.2%) met the criteria for a current depressive disorder. In bivariate analyses, EA was significantly elevated in patients with an anxiety disorder in comparison to those without (54.4 vs. 48.9; p = 0.01). The same was true for depressive disorder (54.9 vs. 48.6; p < 0.01). After controlling for relevant sociodemographic and medical factors, EA did not predict anxiety or depressive disorder in separate regression models. The presence of an anxiety disorder was significantly predicted by female sex, younger age and elevated comorbidity burden. In contrast, the presence of a depressive disorder was predicted by comorbidity burden. Sociodemographic and medical predictors have greater predictive potential than EA regarding current anxiety and depressive disorder in hematological cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.